|
1
|
Ferlay J, Bray F, Pisani P and Parkin M:
GLOBOCAN 2002: cancer incidence, mortality and prevalence
worldwide. Lyon: IARC Press. 2004.
|
|
2
|
Shah MA, Khanin R, Tang L, Janjigian YY,
Klimstra DS, Gerdes H and Kelsen DP: Molecular classification of
gastric cancer: a new paradigm. Clin Cancer Res. 17:2693–2701.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Moiola C, De Luca P, Gardner K, Vazquez E
and De Siervi A: Cyclin T1 overexpression induces malignant
transformation and tumor growth. Cell Cycle. 9:3119–3126. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
De Luca A, De Falco M, Baldi A and Paggi
MG: Cyclin T: three forms for different roles in physiological and
pathological functions. J Cell Physiol. 194:101–107. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
De Luca A, Russo P, Severino A, Baldi A,
Battista T, Cavallotti I, De Luca L, Baldi F, Giordano A and Paggi
MG: Pattern of expression of cyclin T1 in human tissues. J
Histochem Cytochem. 49:685–692. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sano M and Schneider MD: Cyclin-dependent
kinase-9: an RNAPII kinase at the nexus of cardiac growth and death
cascades. Circ Res. 95:867–876. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sano M, Wang SC, Shirai M, Scaglia F, Xie
M, Sakai S, Tanaka T, Kulkarni PA, Barger PM, Youker KA, et al:
Activation of cardiac Cdk9 represses PGC-1 and confers a
predisposition to heart failure. EMBO J. 23:3559–3569. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chiu YL, Cao H, Jacque JM, Stevenson M and
Rana TM: Inhibition of human immunodeficiency virus type 1
replication by RNA interference directed against human
transcription elongation factor P-TEFb (CDK9/CyclinT1). J Virol.
78:2517–2529. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chao SH and Price DH: Flavopiridol
inactivates P-TEFb and blocks most RNA polymerase II transcription
in vivo. J Biol Chem. 276:31793–31799. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Napolitano G, Majello B and Lania L: Role
of cyclinT/Cdk9 complex in basal and regulated transcription
(review). Int J Oncol. 21:171–177. 2002.PubMed/NCBI
|
|
11
|
Chen R, Keating MJ, Gandhi V and Plunkett
W: Transcription inhibition by flavopiridol: mechanism of chronic
lymphocytic leukemia cell death. Blood. 106:2513–2519. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shan B, Zhuo Y, Chin D, Morris CA, Morris
GF and Lasky JA: Cyclin-dependent kinase 9 is required for tumor
necrosis factor-alpha-stimulated matrix metalloproteinase-9
expression in human lung adenocarcinoma cells. J Biol Chem.
280:1103–1011. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sugai T, Tsukahara M, Endoh M, Shioi Y,
Takebe N, Mue Y, Matsushita H, Toyota M and Suzuki K: Analysis of
cell cycle-related proteins in gastric intramucosal
differentiated-type cancers based on mucin phenotypes: a novel
hypothesis of early gastric carcinogenesis based on mucin
phenotype. BMC Gastroenterol. 10:552010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ioachim E: Expression patterns of cyclins
D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1
in colorectal carcinoma: correlation with other cell cycle
regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological
features. Int J Clin Pract. 62:1736–1743. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Motohashi M, Wakui S, Muto T, Suzuki Y,
Shirai M, Takahashi H and Hano H: Cyclin D1/cdk4, estrogen
receptors α and β, in N-methyl-N'-nitro-N-nitrosoguanidine-induced
rat gastric carcinogenesis: immunohistochemical study. J Toxicol
Sci. 36:373–378. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kouraklis G, Katsoulis IE, Theocharis S,
Tsourouflis G, Xipolitas N, Glinavou A, Sioka C and Kostakis A:
Does the expression of cyclin E, pRb and p21 correlate with
prognosis in gastric adenocarcinoma? Dig Dis Sci. 54:1015–1020.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li JQ, Miki H, Wu F, Saoo K, Nishioka M,
Ohmori M and Imaida K: Cyclin A correlates with carcinogenesis and
metastasis and p27(kip1) correlates with lymphatic invasion, in
colorectal neoplasms. Hum Pathol. 33:1006–1015. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mrena J, Wiksten JP, Kokkola A, Nordling
S, Haglund C and Ristimäki A: Prognostic significance of cyclin A
in gastric cancer. Int J Cancer. 119:1897–1901. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yasuda M, Takesue F, Inutsuka S, Honda M,
Nozoe T and Korenaga D: Overexpression of cyclin B1 in gastric
cancer and its clinicopathological significance: an
immunohistological study. J Cancer Res Clin Oncol. 128:412–416.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Washington K: 7th edition of the AJCC
cancer staging manual: Stomach. Ann Surg Oncol. 17:3077–3079. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Berlth F, Bollschweiler E, Drebber U,
Hoelscher AH and Moenig S: Pathohistological classification systems
in gastric cancer: Diagnostic relevance and prognostic value. World
J Gastroenterol. 20:5679–5684. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Leucci E, De Falco G, Onnis A, Cerino G,
Cocco M, Luzzi A, Crupi D, Tigli C, Bellan C, Tosi P, et al: The
role of the Cdk9/Cyclin T1 complex in T cell differentiation. J
Cell Physiol. 212:411–415. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bellan C, De Falco G, Lazzi S, Micheli P,
Vicidomini S, Schürfeld K, Amato T, Palumbo A, Bagella L, Sabattini
E, et al: CDK9/CYCLIN T1 expression during normal lymphoid
differentiation and malignant transformation. J Pathol.
203:946–952. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
MacLachlan TK, Sang N, De Luca A, Puri PL,
Levrero M and Giordano A: Binding of CDK9 to TRAF2. J Cell Biochem.
71:467–478. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fu TJ, Peng J, Lee G, Price DH and Flores
O: Cyclin K functions as a CDK9 regulatory subunit and participates
in RNA polymerase II transcription. J Biol Chem. 274:34527–34530.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bettayeb K, Tirado OM, Marionneau-Lambot
S, Ferandin Y, Lozach O, Morris JC, Mateo-Lozano S, Drueckes P,
Schächtele C, Kubbutat MH, et al: Meriolins, a new class of cell
death inducing kinase inhibitors with enhanced selectivity for
cyclin-dependent kinases. Cancer Res. 67:8325–8334. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
De Falco G and Giordano A: CDK9: From
basal transcription to cancer and AIDS. Cancer Biol Ther.
1:342–377. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee DK, Duan HO and Chang C: Androgen
receptor interacts with the positive elongation factor P-TEFb and
enhances the efficiency of transcriptional elongation. J Biol Chem.
276:9978–9984. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Peng J, Zhu Y, Milton JT and Price DH:
Identification of multiple cyclin subunits of human P-TEFb. Genes
Dev. 12:755–762. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Napolitano G, Majello B, Licciardo P,
Giordano A and Lania L: Transcriptional activity of positive
transcription elongation factor b kinase in vivo requires the
C-terminal domain of RNA polymerase II. Gene. 254:139–145. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Garriga J, Peng J, Parreño M, Price DH,
Henderson EE and Graña X: Upregulation of cyclin T1/CDK9 complexes
during T cell activation. Oncogene. 17:3093–3102. 1998. View Article : Google Scholar : PubMed/NCBI
|
